Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks Consensus Estimate of a loss of $6.4. This compares to a loss of $11.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +30.31%. A quarter ago, it was expected that this company would post a loss of $6.8 per share when it actually produced a loss of $5.8, delivering a surprise of +14.71%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Redwood City, CA 94063 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (650) 665-9295 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fil ...

Exhibit 99.1 Reverse Stock Split Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update REDWOOD CITY, CA, August 14, 2025 – Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody™ ISA ...

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “In the second quarter ...

Financial Performance - Bolt Biotherapeutics reported a quarterly loss of $0.29 per share, better than the Zacks Consensus Estimate of a loss of $0.34, and compared to a loss of $0.28 per share a year ago, indicating an earnings surprise of 14.71% [1] - The company posted revenues of $1.22 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 19.45%, but down from $5.27 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates just once and topped consensus revenue estimates three times [2] Stock Performance - Since the beginning of the year, Bolt Biotherapeutics shares have declined by approximately 33.1%, while the S&P 500 has decreased by 3.8% [3] - The current Zacks Rank for Bolt Biotherapeutics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $0.99 million, and for the current fiscal year, it is -$1.27 on revenues of $3.79 million [7] - The estimate revisions trend for Bolt Biotherapeutics is mixed, and future stock movements will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Biomedical and Genetics industry, to which Bolt Biotherapeutics belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Summary of Bolt Biotherapeutics Conference Call Company Overview - **Company**: Bolt Biotherapeutics (BOLT) - **Focus**: Development of immuno-oncology therapeutics, specifically targeting cancer through innovative antibody platforms Key Points Discussed Financial Overview - As of March 31, cash, cash equivalents, and marketable securities totaled **$58 million** [4] - Funding expected to support key milestones, including the Phase 1 trial for BDC3042 through mid-2026 [4] Clinical Programs - **BDC3042**: A first-in-class dectin-2 agonist antibody aimed at treating cancer - Phase 1 trial results presented at the American Association for Cancer Research (AACR) Annual Meeting [4][25] - **Enrollment**: 17 patients, including those with non-small cell lung cancer (NSCLC) [26] - **Safety Profile**: Well tolerated with no grade 4 or 5 adverse events reported [28] - **Efficacy**: Evidence of tumor size reduction in patients with prior treatments, particularly in NSCLC [31][37] - **BDC4182**: A next-generation immune-stimulating antibody conjugate (ISAC) targeting claudin 18.2 - Enrollment for the first-in-human Phase 1 study has opened in Australia [42] - Targeting advanced gastric and gastroesophageal cancers [50] Mechanism of Action - **BDC3042**: Engages and activates dectin-2 on tumor-associated macrophages (TAMs), converting them into tumor-destructive cells [11][12] - **Clinical Observations**: Enhanced immune response noted, particularly in patients previously treated with checkpoint inhibitors [12][60] Preclinical Data - BDC3042 shows promising preclinical results, indicating potential for broad applicability across various cancer types [15][18] - Evidence of tumor regression in preclinical models, supporting the mechanism of action [19][20] Market Potential - BDC4182 aims to capture a broader market by targeting not only high expressers of claudin 18.2 but also moderate and low expressers [44][81] - The approved drug for claudin 18.2 currently addresses about **38%** of the gastric cancer market [81] Collaboration and Partnerships - Ongoing discussions for partnerships to accelerate the development of BDC3042, with a goal to secure a non-binding term sheet by June 6 [39] - Collaboration with Genmab and Toray to advance multiple development programs [52][53] Future Outlook - Anticipated updates on patient recruitment for BDC4182 and partner selection for BDC3042 by fall [54] - Emphasis on efficiency in the current biotech financing environment to develop product candidates that could improve patient outcomes [54] Additional Insights - The conference highlighted the importance of safety and tolerability in early-phase trials, especially for heavily pretreated patients [28][37] - The potential for BDC3042 to be effective in combination with other therapies, particularly in immunogenic tumors like NSCLC [60][61] - The company is focused on differentiating its ISAC platform from competitors by improving linker payloads and reducing immunogenicity [95][96] This summary encapsulates the critical aspects of the conference call, providing insights into Bolt Biotherapeutics' current status, clinical programs, and future directions in the oncology space.

Financial Performance - Net losses for the three months ended March 31, 2025, were $11.0 million, compared to $10.8 million for the same period in 2024, with an accumulated deficit of $438.4 million as of March 31, 2025[98]. - Collaboration revenue decreased to $1.2 million in Q1 2025 from $5.3 million in Q1 2024, a decline of 77% due to the completion of performance obligations under the Amended Innovent Agreement[120]. - Net loss for Q1 2025 was $11.0 million, slightly higher than the $10.8 million loss in Q1 2024, indicating a 2% increase in losses year-over-year[125]. - Net cash used in operating activities was $13.4 million in Q1 2025 compared to $16.8 million in Q1 2024, a decrease of 20%[128]. - Cash and cash equivalents, along with marketable securities, totaled $58.0 million as of March 31, 2025, expected to fund operations through mid-2026[125]. - The accumulated deficit reached $438.4 million as of March 31, 2025, reflecting ongoing financial challenges[125]. - The company anticipates continuing to incur net losses and has substantial doubt about its ability to continue as a going concern within one year after the issuance of the financial statements[125]. Revenue Sources - The company has not recorded any revenue from product sales, with revenue solely derived from collaborations with Toray, Genmab, and Innovent[96]. - Collaboration revenue is expected to fluctuate based on the timing and outcome of development activities and payments from collaboration partners[106]. Research and Development - BDC-3042, a dectin-2 agonist antibody program, received FDA IND clearance in July 2023 and began dosing patients in a Phase 1 study in October 2023, with favorable results reported in April 2025[92]. - BDC-4182, targeting claudin 18.2, is expected to begin its first-in-human Phase 1 trial in the second quarter of 2025, following positive preclinical results[93]. - Research and development expenses were $9.5 million in Q1 2025, down from $16.5 million in Q1 2024, reflecting a 43% reduction primarily due to lower personnel-related costs and discontinued clinical development[121]. Operational Changes - The restructuring plan announced in May 2024 resulted in a workforce reduction of approximately 50 employees, or 50% of the workforce, with total restructuring charges estimated at $3.6 million[94]. - General and administrative expenses decreased to $3.8 million in Q1 2025 from $5.8 million in Q1 2024, a reduction of 35% attributed to restructuring and lower consulting costs[122]. - The establishment of a wholly-owned subsidiary in Australia in October 2024 aims to enhance research and development capabilities and strengthen partnerships in the Australian life sciences market[97]. Future Outlook - The company anticipates continued significant operating losses as it conducts ongoing and planned clinical trials and research and development programs[98]. - Future capital requirements will depend on various factors, including clinical trial costs and the success of collaborations, with significant uncertainty regarding funding availability[134]. - Macroeconomic factors, including inflation and interest rates, are anticipated to impact the company's business and financial condition[100].

Financial Performance - Collaboration revenue for Q1 2025 was $1.2 million, a decrease of 77% from $5.3 million in Q1 2024[14] - Loss from operations for Q1 2025 was $12.1 million, compared to a loss of $17.1 million in Q1 2024, representing a 29% improvement[14] - Net loss for Q1 2025 was $11.0 million, compared to a net loss of $10.8 million in Q1 2024[14] - Net loss for Q1 2025 was $11,040,000, compared to a net loss of $10,811,000 in Q1 2024, representing an increase in loss of approximately 2.1%[18] Expenses - Research and Development (R&D) expenses decreased to $9.5 million in Q1 2025 from $16.5 million in Q1 2024, reflecting a reduction of 42%[14] - General and Administrative (G&A) expenses were $3.8 million in Q1 2025, down 35% from $5.8 million in Q1 2024[14] - Cash used in operating activities decreased to $13,365,000 in Q1 2025 from $16,751,000 in Q1 2024, a reduction of about 20.5%[18] - Depreciation and amortization expenses decreased to $399,000 in Q1 2025 from $458,000 in Q1 2024, a decline of about 12.9%[18] - Stock-based compensation expense significantly decreased to $709,000 in Q1 2025 from $2,302,000 in Q1 2024, a reduction of approximately 69.1%[18] - Changes in accounts payable and accrued expenses improved, decreasing to $2,511,000 in Q1 2025 from $3,544,000 in Q1 2024, a decrease of about 29.0%[18] Cash and Assets - Cash balance as of March 31, 2025, was $58.0 million, expected to fund operations through mid-2026[5] - Total assets decreased to $85.9 million as of March 31, 2025, from $99.6 million at the end of 2024[16] - Cash, cash equivalents, and restricted cash at the end of Q1 2025 totaled $10,156,000, up from $6,027,000 at the end of Q1 2024, an increase of about 68.5%[18] - Total cash and cash equivalents increased to $8,391,000 in Q1 2025 from $4,262,000 in Q1 2024, marking a growth of approximately 96.5%[18] Investment Activities - Net cash provided by investing activities increased to $14,551,000 in Q1 2025, compared to $10,203,000 in Q1 2024, reflecting a growth of approximately 42.9%[18] - Maturities of marketable securities decreased to $14,580,000 in Q1 2025 from $33,261,000 in Q1 2024, a decline of approximately 56.2%[18] - The company reported a gain on the sale of property and equipment amounting to $288,000 in Q1 2025, with no comparable figure in Q1 2024[18] Clinical Development - BDC-3042 Phase 1 dose-escalation study demonstrated a favorable safety profile and dose-dependent biological activity[5] - BDC-4182 Phase 1 study for gastric and gastroesophageal cancer opened for enrollment in April 2025[6] - Bolt Biotherapeutics is seeking a partner to accelerate the development of BDC-3042[5]

Core Insights - Bolt Biotherapeutics reported financial results for Q1 2025, highlighting advancements in their immunotherapy pipeline and a cash balance of $58 million to fund operations through mid-2026 [1][4][10]. Business Update - The company is advancing its pipeline of novel immunotherapies, with promising early clinical data for BDC-3042 presented at AACR 2025 and the opening of enrollment for BDC-4182 [2][4]. - BDC-3042, a proprietary agonist antibody targeting dectin-2, showed a favorable safety profile and anti-tumor activity in a Phase 1 study for patients with metastatic solid tumors [5]. - BDC-4182, targeting claudin 18.2, has opened for enrollment and demonstrated complete regressions in preclinical models [5]. Financial Performance - Collaboration revenue decreased to $1.2 million in Q1 2025 from $5.3 million in Q1 2024, primarily due to the completion of performance obligations under a previous agreement [10]. - Research and Development (R&D) expenses were $9.5 million in Q1 2025, down from $16.5 million in Q1 2024, attributed to reduced clinical expenses and restructuring [10]. - General and Administrative (G&A) expenses also decreased to $3.8 million from $5.8 million year-over-year [10]. - The net loss for Q1 2025 was $11.0 million, compared to a net loss of $10.8 million in Q1 2024 [12]. Cash Position - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $58 million, expected to support operations through mid-2026 [4][10].

Core Insights - Bolt Biotherapeutics is hosting a KOL conference call and webcast on May 12, 2025, featuring Dr. Ecaterina Dumbrava discussing the Phase 1 clinical study results of BDC-3042 [1][2] - The management team will also provide updates on BDC-4182 clinical development and first quarter 2025 financial results, followed by a live Q&A session [2] Company Overview - Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment [4] - The company's pipeline includes BDC-3042, a first-in-class agonist antibody targeting dectin-2, and BDC-4182, a next-generation Immune-Stimulating Antibody Conjugate (ISAC) targeting claudin 18.2 [4] - BDC-3042 is currently in a Phase 1 dose escalation trial involving patients with seven different solid tumor types, while BDC-4182 is expected to initiate clinical trials in Q2 2025 [4]